Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BGM
BGM Group
$11.97
-6.6%
$12.57
$5.26
$17.17
$1.16B1.3833,953 shs86,258 shs
Epizyme, Inc. stock logo
EPZM
Epizyme
$1.47
$1.47
$0.41
$5.80
$247.44M-0.413.23 million shs7,960 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.32
$1.33
$1.19
$2.04
$1.05B1.393.88 million shs8.19 million shs
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$9.04
-2.8%
$10.88
$8.58
$25.07
$777.86M0.741.83 million shs3.24 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BGM
BGM Group
-6.63%-8.42%+3.46%+5.46%+1,196,999,900.00%
Epizyme, Inc. stock logo
EPZM
Epizyme
0.00%0.00%0.00%0.00%0.00%
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.00%+2.33%+1.54%-22.35%+3.13%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-2.80%-4.64%-10.67%-31.41%-54.53%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BGM
BGM Group
N/AN/AN/AN/AN/AN/AN/AN/A
Epizyme, Inc. stock logo
EPZM
Epizyme
N/AN/AN/AN/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
4.4972 of 5 stars
3.42.00.04.42.15.00.6
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
3.2017 of 5 stars
3.51.00.04.41.80.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BGM
BGM Group
0.00
N/AN/AN/A
Epizyme, Inc. stock logo
EPZM
Epizyme
0.00
N/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.75
Moderate Buy$2.75108.33% Upside
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
2.90
Moderate Buy$35.80296.02% Upside

Current Analyst Ratings Breakdown

Latest EPZM, SNDX, OPK, and BGM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$16.00 ➝ $17.00
5/6/2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
5/1/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
4/25/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral
4/7/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BGM
BGM Group
$25.10M46.36N/AN/A$7.34 per share1.63
Epizyme, Inc. stock logo
EPZM
Epizyme
$37.43M6.61N/AN/A($0.54) per share-2.72
OPKO Health, Inc. stock logo
OPK
OPKO Health
$713.10M1.47$0.07 per share19.19$2.00 per share0.66
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$23.68M32.85N/AN/A$3.38 per share2.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BGM
BGM Group
-$1.44MN/A0.00N/AN/AN/AN/AN/A
Epizyme, Inc. stock logo
EPZM
Epizyme
-$251.12M-$1.72N/AN/AN/A-391.90%-2,459.33%-69.74%N/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$53.22M-$0.07N/AN/AN/A-5.66%-2.85%-1.82%8/6/2025 (Estimated)
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$318.76M-$3.86N/AN/AN/A-757.53%-101.60%-58.41%8/7/2025 (Estimated)

Latest EPZM, SNDX, OPK, and BGM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2025Q1 2025
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$1.04-$0.98+$0.06-$0.98$15.88 million$20.04 million
4/30/2025Q1 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.10-$0.03-$0.10$163.13 million$149.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BGM
BGM Group
N/AN/AN/AN/AN/A
Epizyme, Inc. stock logo
EPZM
Epizyme
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BGM
BGM Group
N/A
3.39
2.82
Epizyme, Inc. stock logo
EPZM
Epizyme
N/A
5.35
5.19
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.25
2.49
2.28
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
1.53
5.80
5.75

Institutional Ownership

CompanyInstitutional Ownership
BGM
BGM Group
N/A
Epizyme, Inc. stock logo
EPZM
Epizyme
76.45%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
BGM
BGM Group
58.66%
Epizyme, Inc. stock logo
EPZM
Epizyme
23.40%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
4.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
BGM
BGM Group
29897.22 million40.19 millionN/A
Epizyme, Inc. stock logo
EPZM
Epizyme
250168.33 million128.97 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
2,997793.05 million398.99 millionOptionable
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
11086.05 million82.52 millionOptionable

Recent News About These Companies

Syndax Pharmaceuticals, Inc. (SNDX) - Yahoo Finance
SNDX Syndax Pharmaceuticals, Inc. - Seeking Alpha
Syndax Pharmaceuticals Inc News (SNDX) - Investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGM Group NASDAQ:BGM

$11.97 -0.85 (-6.63%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$12.53 +0.56 (+4.68%)
As of 06/27/2025 04:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Epizyme stock logo

Epizyme NASDAQ:EPZM

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.32 0.00 (0.00%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$1.32 +0.00 (+0.30%)
As of 06/27/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Syndax Pharmaceuticals stock logo

Syndax Pharmaceuticals NASDAQ:SNDX

$9.04 -0.26 (-2.80%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$9.18 +0.15 (+1.60%)
As of 06/27/2025 07:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.